A New Frontier in Cancer Research: FAH (FAAA_HUMAN), A Potential Drug Target and Biomarker

Target Name: FAH

NCBI ID: G2184

Content of Review Report on FAH Target / Biomarker

FAH

A New Frontier in Cancer Research: FAH (FAAA_HUMAN), A Potential Drug Target and Biomarker

Cancer is one of the leading causes of morbidity and mortality worldwide, affecting millions of people each year. The search for new treatments and biomarkers to combat this relentless disease has led to the exploration of various novel targets, including the FAAA gene family. In this article, we will discuss the FAH (FAAA_HUMAN) gene, its potential as a drug target and biomarker in the fight against cancer.

The FAAA gene Family

The FAAA gene family is a member of the superfamily of ATP-binding proteins, known as the A-type ATPases. These proteins are involved in various cellular processes, including metabolism, stress response, and signal transduction. The FAAA gene is a member of this family and has been identified as a potential drug target in cancer.

Expression of the FAAA gene

The FAAA gene is expressed in various tissues and organs, including the brain, heart, skeletal muscles, and organs. It is also expressed in various cell types, including cancer cells. The expression of the FAAA gene has been associated with the development and progression of various diseases, including cancer.

Potential drug targets

The FAAA gene has been identified as a potential drug target due to its involvement in various cellular processes that are linked to cancer. One of the key features of the FAAA gene is its role in cell signaling pathways, including the regulation of cell growth, apoptosis, and angiogenesis.

FAH has been shown to play a crucial role in these processes, and its knockdown has been shown to inhibit the growth and survival of cancer cells. Additionally, FAH has been shown to promote the formation of blood-brain barrier (BBB), a critical barrier that protects the brain from external substances.

Biomarkers

The FAAA gene has also been identified as a potential biomarker for cancer. The expression of the FAAA gene has been shown to be associated with the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers.

FAH has also been shown to be a potential biomarker for cancer-related apoptosis, as its expression has been associated with the loss of cell life in cancer cells. Additionally, the FAAA gene has been shown to be involved in the regulation of cellular stress, which is a key factor in the development of cancer.

Conclusion

In conclusion, the FAAA gene family, including the FAH gene, has been shown to be involved in various cellular processes that are linked to the development and progression of cancer. Its potential as a drug target and biomarker makes it an attractive target for cancer researchers to explore. Further studies are needed to fully understand the role of the FAAA gene in cancer and to develop effective treatments.

Protein Name: Fumarylacetoacetate Hydrolase

The "FAH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets